CompletedPhase 2ketamine

CAP-Ketamine for Antidepressant Resistant PTSD

Sponsored by VA Office of Research and Development

NCT ID
NCT02655692
Target Enrollment
163 participants
Start Date
2016-04-18
Est. Completion
2020-07-01

About This Study

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.

Conditions Studied

PTSDPosttraumatic Stress Disorder

Interventions

  • •Ketamine
  • •Placebo/Saline

Eligibility

Age:18 Years - 70 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* male or female Veterans or active duty military personnel between the ages of 18 and 70 years
* diagnosis of PTSD
* history of trialing one or more antidepressant medications with little to no PTSD symptom improvement
* ability to provide written informed consent

Exclusion Criteria:

* females who are currently pregnant or breastfeeding
* current high risk for suicide
* history of severe head injury

Study Locations (3)

VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut, United States
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, United States
Brooke Army Medical Center
San Antonio, Texas, United States

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

CAP-Ketamine for Antidepressant Resistant PTSD | Huxley